Daniel M Moreira1, Lauren E Howard2, Katharine N Sourbeer3, Hiruni S Amarasekara3, Lydia C Chow3, Dillon C Cockrell3, Connor L Pratson3, Brian T Hanyok3, William J Aronson4, Christopher J Kane5, Martha K Terris6, Christopher L Amling7, Matthew R Cooperberg8, Stephen J Freedland9. 1. Department of Urology, University of Illinois at Chicago, Chicago, IL. Electronic address: moreira@uic.edu. 2. Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC; Urology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC. 3. Urology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC. 4. Urology Section, Department of Surgery, Veterans Affairs Medical Center, Greater Los Angeles, Los Angeles, CA; Department of Urology, University of California at Los Angeles Medical Center, Los Angeles, CA. 5. Division of Urology, Department of Surgery, University of California at San Diego Medical Center, San Diego, CA. 6. Urology Section, Division of Surgery, Veterans Affairs Medical Centers and Division of Urologic Surgery, Department of Surgery, Medical College of Georgia, Augusta, GA. 7. Division of Urology, Department of Surgery, Oregon Health and Science University, Portland, OR. 8. Departments of Urology and Epidemiology and Biostatistics, University of California, San Francisco and Urology Section, Department of Surgery, Veterans Affairs Medical Center, San Francisco, CA. 9. Urology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Abstract
OBJECTIVE: To identify the predictors of time from initial diagnosis of metastatic castration-resistance prostate cancer (mCRPC) to all-cause death within the Shared Equal Access Regional Cancer Hospital cohort. PATIENTS AND METHODS: We performed a retrospective analysis of 205 mCRPC men. Overall survival was estimated and plotted using the Kaplan-Meier method. The uni- and multivariable overall survival predictors were evaluated with the Cox proportional hazards model. A nomogram was generated to predict overall survival at 1, 2, 3, and 5 years after mCRPC. Concordance index and calibration plot were obtained. RESULTS: A total of 170 men (83%) died over a median follow-up of 41 months. In univariable analysis, older age, more remote year of mCRPC, nonblack race, greater number of bone metastasis, higher prostate-specific antigen (PSA) levels, shorter PSA doubling time, and faster PSA velocity at mCRPC diagnosis were significantly associated with shorter overall survival (all P < .05). In multivariable analysis, older age, more remote year of mCRPC, greater number of bone metastasis, higher PSA levels, and shorter PSA doubling time at mCRPC diagnosis remained significantly associated with shorter overall survival (all P < .05). On the basis of these variables, a nomogram was generated yielding a concordance index of 0.67 and good calibration. CONCLUSION: The use of clinical parameter such as age, disease burden, and PSA levels and kinetics can be used to estimate overall survival in mCRPC patients.
OBJECTIVE: To identify the predictors of time from initial diagnosis of metastatic castration-resistance prostate cancer (mCRPC) to all-cause death within the Shared Equal Access Regional Cancer Hospital cohort. PATIENTS AND METHODS: We performed a retrospective analysis of 205 mCRPC men. Overall survival was estimated and plotted using the Kaplan-Meier method. The uni- and multivariable overall survival predictors were evaluated with the Cox proportional hazards model. A nomogram was generated to predict overall survival at 1, 2, 3, and 5 years after mCRPC. Concordance index and calibration plot were obtained. RESULTS: A total of 170 men (83%) died over a median follow-up of 41 months. In univariable analysis, older age, more remote year of mCRPC, nonblack race, greater number of bone metastasis, higher prostate-specific antigen (PSA) levels, shorter PSA doubling time, and faster PSA velocity at mCRPC diagnosis were significantly associated with shorter overall survival (all P < .05). In multivariable analysis, older age, more remote year of mCRPC, greater number of bone metastasis, higher PSA levels, and shorter PSA doubling time at mCRPC diagnosis remained significantly associated with shorter overall survival (all P < .05). On the basis of these variables, a nomogram was generated yielding a concordance index of 0.67 and good calibration. CONCLUSION: The use of clinical parameter such as age, disease burden, and PSA levels and kinetics can be used to estimate overall survival in mCRPC patients.
Authors: Andrew J Armstrong; Ian F Tannock; Ronald de Wit; Daniel J George; Mario Eisenberger; Susan Halabi Journal: Eur J Cancer Date: 2009-12-11 Impact factor: 9.162
Authors: Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small Journal: J Clin Oncol Date: 2014-01-21 Impact factor: 44.544
Authors: D M Moreira; M R Cooperberg; L E Howard; W J Aronson; C J Kane; M K Terris; C L Amling; M Kuchibhatla; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2014-01-14 Impact factor: 5.554
Authors: Ethan Basch; Karen Autio; Charles J Ryan; Peter Mulders; Neal Shore; Thian Kheoh; Karim Fizazi; Christopher J Logothetis; Dana Rathkopf; Matthew R Smith; Paul N Mainwaring; Yanni Hao; Thomas Griffin; Susan Li; Michael L Meyers; Arturo Molina; Charles Cleeland Journal: Lancet Oncol Date: 2013-09-25 Impact factor: 41.316
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544
Authors: D M Moreira; L E Howard; K N Sourbeer; H S Amarasekara; L C Chow; D C Cockrell; B T Hanyok; C L Pratson; W J Aronson; C J Kane; M K Terris; C L Amling; M R Cooperberg; A Liede; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2015-05-26 Impact factor: 5.554
Authors: Lauren E Howard; Daniel M Moreira; Amanda De Hoedt; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Martha K Terris; Stephen J Freedland Journal: BJU Int Date: 2017-04-30 Impact factor: 5.588
Authors: Mei-Chun Yeh; Brian W C Tse; Nicholas L Fletcher; Zachary H Houston; Maria Lund; Marianna Volpert; Chelsea Stewart; Kamil A Sokolowski; Varinder Jeet; Kristofer J Thurecht; Douglas H Campbell; Bradley J Walsh; Colleen C Nelson; Pamela J Russell Journal: EJNMMI Res Date: 2020-05-07 Impact factor: 3.138
Authors: Adeline N Boettcher; Ahmed Usman; Alicia Morgans; David J VanderWeele; Jeffrey Sosman; Jennifer D Wu Journal: Front Oncol Date: 2019-09-11 Impact factor: 6.244
Authors: Erik M Velez; Bhushan Desai; Lingyun Ji; David I Quinn; Patrick M Colletti; Hossein Jadvar Journal: Theranostics Date: 2020-02-10 Impact factor: 11.556